nodes	percent_of_prediction	percent_of_DWPC	metapath
Dinoprostone—PTGER4—ankylosing spondylitis	0.568	1	CbGaD
Dinoprostone—SLCO3A1—Methotrexate—ankylosing spondylitis	0.0542	0.148	CbGbCtD
Dinoprostone—CYP11A1—Dexamethasone—ankylosing spondylitis	0.0408	0.112	CbGbCtD
Dinoprostone—SLCO1C1—Methotrexate—ankylosing spondylitis	0.0346	0.0947	CbGbCtD
Dinoprostone—CYP19A1—Betamethasone—ankylosing spondylitis	0.0326	0.0893	CbGbCtD
Dinoprostone—SLCO1B1—Sulfasalazine—ankylosing spondylitis	0.0281	0.0768	CbGbCtD
Dinoprostone—SLCO1A2—Prednisolone—ankylosing spondylitis	0.0252	0.0689	CbGbCtD
Dinoprostone—SLCO1A2—Prednisone—ankylosing spondylitis	0.0238	0.0651	CbGbCtD
Dinoprostone—CYP19A1—Dexamethasone—ankylosing spondylitis	0.019	0.0519	CbGbCtD
Dinoprostone—SLC22A11—Methotrexate—ankylosing spondylitis	0.0179	0.0489	CbGbCtD
Dinoprostone—SLC22A7—Methotrexate—ankylosing spondylitis	0.017	0.0466	CbGbCtD
Dinoprostone—ABCC4—Methotrexate—ankylosing spondylitis	0.0166	0.0455	CbGbCtD
Dinoprostone—SLCO1A2—Dexamethasone—ankylosing spondylitis	0.0149	0.0406	CbGbCtD
Dinoprostone—SLCO1A2—Methotrexate—ankylosing spondylitis	0.0119	0.0327	CbGbCtD
Dinoprostone—SLCO1B1—Methotrexate—ankylosing spondylitis	0.0113	0.0308	CbGbCtD
Dinoprostone—SLC22A8—Methotrexate—ankylosing spondylitis	0.0104	0.0284	CbGbCtD
Dinoprostone—SLC22A6—Methotrexate—ankylosing spondylitis	0.00724	0.0198	CbGbCtD
Dinoprostone—Misoprostol—PTGER4—ankylosing spondylitis	0.00453	1	CrCbGaD
Dinoprostone—PTGER2—Prostanoid ligand receptors—PTGER4—ankylosing spondylitis	0.00325	0.0752	CbGpPWpGaD
Dinoprostone—PTGER3—Prostanoid ligand receptors—PTGER4—ankylosing spondylitis	0.003	0.0694	CbGpPWpGaD
Dinoprostone—PTGFR—Prostanoid ligand receptors—PTGER4—ankylosing spondylitis	0.00224	0.0519	CbGpPWpGaD
Dinoprostone—PTGIR—Prostanoid ligand receptors—PTGER4—ankylosing spondylitis	0.00219	0.0508	CbGpPWpGaD
Dinoprostone—PTGER1—Prostanoid ligand receptors—PTGER4—ankylosing spondylitis	0.00219	0.0508	CbGpPWpGaD
Dinoprostone—PTGER2—Eicosanoid ligand-binding receptors—PTGER4—ankylosing spondylitis	0.00216	0.05	CbGpPWpGaD
Dinoprostone—PTGER3—Eicosanoid ligand-binding receptors—PTGER4—ankylosing spondylitis	0.00199	0.0461	CbGpPWpGaD
Dinoprostone—PTGER2—Small Ligand GPCRs—PTGER4—ankylosing spondylitis	0.00179	0.0413	CbGpPWpGaD
Dinoprostone—PTGER3—Small Ligand GPCRs—PTGER4—ankylosing spondylitis	0.00165	0.0382	CbGpPWpGaD
Dinoprostone—PTGFR—Eicosanoid ligand-binding receptors—PTGER4—ankylosing spondylitis	0.00149	0.0345	CbGpPWpGaD
Dinoprostone—PTGIR—Eicosanoid ligand-binding receptors—PTGER4—ankylosing spondylitis	0.00146	0.0337	CbGpPWpGaD
Dinoprostone—PTGER1—Eicosanoid ligand-binding receptors—PTGER4—ankylosing spondylitis	0.00146	0.0337	CbGpPWpGaD
Dinoprostone—PTGER2—Prostaglandin Synthesis and Regulation—PTGER4—ankylosing spondylitis	0.00124	0.0287	CbGpPWpGaD
Dinoprostone—PTGFR—Small Ligand GPCRs—PTGER4—ankylosing spondylitis	0.00123	0.0285	CbGpPWpGaD
Dinoprostone—PTGIR—Small Ligand GPCRs—PTGER4—ankylosing spondylitis	0.00121	0.0279	CbGpPWpGaD
Dinoprostone—PTGER1—Small Ligand GPCRs—PTGER4—ankylosing spondylitis	0.00121	0.0279	CbGpPWpGaD
Dinoprostone—PTGER3—Prostaglandin Synthesis and Regulation—PTGER4—ankylosing spondylitis	0.00114	0.0265	CbGpPWpGaD
Dinoprostone—PTGFR—Prostaglandin Synthesis and Regulation—PTGER4—ankylosing spondylitis	0.000855	0.0198	CbGpPWpGaD
Dinoprostone—PTGIR—Prostaglandin Synthesis and Regulation—PTGER4—ankylosing spondylitis	0.000837	0.0194	CbGpPWpGaD
Dinoprostone—PTGER1—Prostaglandin Synthesis and Regulation—PTGER4—ankylosing spondylitis	0.000837	0.0194	CbGpPWpGaD
Dinoprostone—CYP11A1—Prostaglandin Synthesis and Regulation—PTGER4—ankylosing spondylitis	0.00063	0.0146	CbGpPWpGaD
Dinoprostone—SLCO2A1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000404	0.00935	CbGpPWpGaD
Dinoprostone—PTGER2—G alpha (s) signalling events—PTGER4—ankylosing spondylitis	0.000398	0.00922	CbGpPWpGaD
Dinoprostone—SLCO3A1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000383	0.00887	CbGpPWpGaD
Dinoprostone—SLCO4A1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000365	0.00846	CbGpPWpGaD
Dinoprostone—ABCC5—Defective B3GAT3 causes JDSSDHD—B3GNT2—ankylosing spondylitis	0.000349	0.00807	CbGpPWpGaD
Dinoprostone—Neck stiffness—Methotrexate—ankylosing spondylitis	0.000313	0.0164	CcSEcCtD
Dinoprostone—SLCO1C1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000306	0.00709	CbGpPWpGaD
Dinoprostone—Nuchal rigidity—Methotrexate—ankylosing spondylitis	0.000288	0.015	CcSEcCtD
Dinoprostone—PTGIR—G alpha (s) signalling events—PTGER4—ankylosing spondylitis	0.000269	0.00623	CbGpPWpGaD
Dinoprostone—HPGDS—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	0.000252	0.00583	CbGpPWpGaD
Dinoprostone—Hiccups—Prednisolone—ankylosing spondylitis	0.000246	0.0128	CcSEcCtD
Dinoprostone—Inflammation—Methylprednisolone—ankylosing spondylitis	0.000232	0.0121	CcSEcCtD
Dinoprostone—Hiccups—Triamcinolone—ankylosing spondylitis	0.000226	0.0118	CcSEcCtD
Dinoprostone—Hiccups—Methylprednisolone—ankylosing spondylitis	0.000225	0.0118	CcSEcCtD
Dinoprostone—SLCO2B1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000222	0.00514	CbGpPWpGaD
Dinoprostone—PTGER2—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000222	0.00513	CbGpPWpGaD
Dinoprostone—Wheezing—Triamcinolone—ankylosing spondylitis	0.000219	0.0115	CcSEcCtD
Dinoprostone—ABCC5—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000212	0.00491	CbGpPWpGaD
Dinoprostone—Hiccups—Dexamethasone—ankylosing spondylitis	0.000205	0.0107	CcSEcCtD
Dinoprostone—Hiccups—Betamethasone—ankylosing spondylitis	0.000205	0.0107	CcSEcCtD
Dinoprostone—PTGER3—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000205	0.00473	CbGpPWpGaD
Dinoprostone—SLC22A11—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000201	0.00466	CbGpPWpGaD
Dinoprostone—PTGER2—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.00019	0.0044	CbGpPWpGaD
Dinoprostone—ABCC5—Carbohydrate metabolism—B3GNT2—ankylosing spondylitis	0.000187	0.00433	CbGpPWpGaD
Dinoprostone—Anaphylactoid reaction—Prednisolone—ankylosing spondylitis	0.000184	0.00963	CcSEcCtD
Dinoprostone—SLC22A7—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000183	0.00423	CbGpPWpGaD
Dinoprostone—Hiccups—Prednisone—ankylosing spondylitis	0.000179	0.00933	CcSEcCtD
Dinoprostone—PTGER3—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000175	0.00406	CbGpPWpGaD
Dinoprostone—Cardiac arrest—Prednisolone—ankylosing spondylitis	0.00017	0.00886	CcSEcCtD
Dinoprostone—Anaphylactoid reaction—Triamcinolone—ankylosing spondylitis	0.000169	0.00886	CcSEcCtD
Dinoprostone—Anaphylactoid reaction—Methylprednisolone—ankylosing spondylitis	0.000169	0.00884	CcSEcCtD
Dinoprostone—Musculoskeletal stiffness—Methotrexate—ankylosing spondylitis	0.000166	0.00869	CcSEcCtD
Dinoprostone—Skin discolouration—Methotrexate—ankylosing spondylitis	0.000165	0.00863	CcSEcCtD
Dinoprostone—Eye pain—Dexamethasone—ankylosing spondylitis	0.000165	0.00861	CcSEcCtD
Dinoprostone—Eye pain—Betamethasone—ankylosing spondylitis	0.000165	0.00861	CcSEcCtD
Dinoprostone—Cardiac arrest—Triamcinolone—ankylosing spondylitis	0.000156	0.00815	CcSEcCtD
Dinoprostone—Cardiac arrest—Methylprednisolone—ankylosing spondylitis	0.000156	0.00813	CcSEcCtD
Dinoprostone—Inflammation—Methotrexate—ankylosing spondylitis	0.000154	0.00804	CcSEcCtD
Dinoprostone—Anaphylactoid reaction—Dexamethasone—ankylosing spondylitis	0.000154	0.00804	CcSEcCtD
Dinoprostone—Anaphylactoid reaction—Betamethasone—ankylosing spondylitis	0.000154	0.00804	CcSEcCtD
Dinoprostone—SLC22A8—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000153	0.00355	CbGpPWpGaD
Dinoprostone—PTGFR—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.000153	0.00354	CbGpPWpGaD
Dinoprostone—Sweating increased—Prednisolone—ankylosing spondylitis	0.00015	0.00785	CcSEcCtD
Dinoprostone—PTGIR—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.00015	0.00347	CbGpPWpGaD
Dinoprostone—PTGER1—GPCRs, Class A Rhodopsin-like—PTGER4—ankylosing spondylitis	0.00015	0.00347	CbGpPWpGaD
Dinoprostone—Vaginal inflammation—Methotrexate—ankylosing spondylitis	0.000149	0.0078	CcSEcCtD
Dinoprostone—ABCC4—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000147	0.00341	CbGpPWpGaD
Dinoprostone—PTGER2—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000145	0.00335	CbGpPWpGaD
Dinoprostone—Asthma—Triamcinolone—ankylosing spondylitis	0.000142	0.00741	CcSEcCtD
Dinoprostone—Cardiac arrest—Betamethasone—ankylosing spondylitis	0.000142	0.0074	CcSEcCtD
Dinoprostone—Cardiac arrest—Dexamethasone—ankylosing spondylitis	0.000142	0.0074	CcSEcCtD
Dinoprostone—Vaginal infection—Methotrexate—ankylosing spondylitis	0.000141	0.00736	CcSEcCtD
Dinoprostone—Bronchospasm—Methylprednisolone—ankylosing spondylitis	0.000139	0.00727	CcSEcCtD
Dinoprostone—CYP11A1—Corticotropin-releasing hormone—TLR4—ankylosing spondylitis	0.000139	0.00321	CbGpPWpGaD
Dinoprostone—Sweating increased—Triamcinolone—ankylosing spondylitis	0.000138	0.00722	CcSEcCtD
Dinoprostone—Sweating increased—Methylprednisolone—ankylosing spondylitis	0.000138	0.0072	CcSEcCtD
Dinoprostone—SLCO1A2—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000136	0.00315	CbGpPWpGaD
Dinoprostone—Acute coronary syndrome—Prednisolone—ankylosing spondylitis	0.000136	0.00708	CcSEcCtD
Dinoprostone—Myocardial infarction—Prednisolone—ankylosing spondylitis	0.000135	0.00704	CcSEcCtD
Dinoprostone—PTGER3—GPCR ligand binding—PTGER4—ankylosing spondylitis	0.000133	0.00309	CbGpPWpGaD
Dinoprostone—PTGFR—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000131	0.00303	CbGpPWpGaD
Dinoprostone—PTGIR—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000128	0.00297	CbGpPWpGaD
Dinoprostone—PTGER1—Class A/1 (Rhodopsin-like receptors)—PTGER4—ankylosing spondylitis	0.000128	0.00297	CbGpPWpGaD
Dinoprostone—SLC22A6—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000128	0.00296	CbGpPWpGaD
Dinoprostone—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000126	0.00292	CbGpPWpGaD
Dinoprostone—Sweating increased—Dexamethasone—ankylosing spondylitis	0.000125	0.00655	CcSEcCtD
Dinoprostone—Sweating increased—Betamethasone—ankylosing spondylitis	0.000125	0.00655	CcSEcCtD
Dinoprostone—Acute coronary syndrome—Triamcinolone—ankylosing spondylitis	0.000125	0.00651	CcSEcCtD
Dinoprostone—Acute coronary syndrome—Methylprednisolone—ankylosing spondylitis	0.000124	0.0065	CcSEcCtD
Dinoprostone—Myocardial infarction—Triamcinolone—ankylosing spondylitis	0.000124	0.00647	CcSEcCtD
Dinoprostone—Myocardial infarction—Methylprednisolone—ankylosing spondylitis	0.000124	0.00646	CcSEcCtD
Dinoprostone—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—ankylosing spondylitis	0.000123	0.00286	CbGpPWpGaD
Dinoprostone—Cardiac arrest—Prednisone—ankylosing spondylitis	0.000123	0.00644	CcSEcCtD
Dinoprostone—SLCO1B1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000116	0.0027	CbGpPWpGaD
Dinoprostone—Acute coronary syndrome—Betamethasone—ankylosing spondylitis	0.000113	0.00591	CcSEcCtD
Dinoprostone—Acute coronary syndrome—Dexamethasone—ankylosing spondylitis	0.000113	0.00591	CcSEcCtD
Dinoprostone—Pharyngitis—Triamcinolone—ankylosing spondylitis	0.000113	0.00588	CcSEcCtD
Dinoprostone—Myocardial infarction—Betamethasone—ankylosing spondylitis	0.000112	0.00587	CcSEcCtD
Dinoprostone—Myocardial infarction—Dexamethasone—ankylosing spondylitis	0.000112	0.00587	CcSEcCtD
Dinoprostone—Anaphylactoid reaction—Methotrexate—ankylosing spondylitis	0.000112	0.00585	CcSEcCtD
Dinoprostone—Arrhythmia—Prednisolone—ankylosing spondylitis	0.00011	0.00576	CcSEcCtD
Dinoprostone—Sweating increased—Prednisone—ankylosing spondylitis	0.000109	0.0057	CcSEcCtD
Dinoprostone—SLC22A2—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	0.000107	0.00247	CbGpPWpGaD
Dinoprostone—Angiopathy—Methylprednisolone—ankylosing spondylitis	0.000103	0.00537	CcSEcCtD
Dinoprostone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.000103	0.00238	CbGpPWpGaD
Dinoprostone—Immune system disorder—Methylprednisolone—ankylosing spondylitis	0.000102	0.00534	CcSEcCtD
Dinoprostone—Arrhythmia—Triamcinolone—ankylosing spondylitis	0.000101	0.0053	CcSEcCtD
Dinoprostone—Vision blurred—Prednisolone—ankylosing spondylitis	0.000101	0.00529	CcSEcCtD
Dinoprostone—Arrhythmia—Methylprednisolone—ankylosing spondylitis	0.000101	0.00529	CcSEcCtD
Dinoprostone—PTGFR—GPCR ligand binding—PTGER4—ankylosing spondylitis	9.98e-05	0.00231	CbGpPWpGaD
Dinoprostone—SLC22A1—Transmembrane transport of small molecules—ANO6—ankylosing spondylitis	9.95e-05	0.0023	CbGpPWpGaD
Dinoprostone—Acute coronary syndrome—Prednisone—ankylosing spondylitis	9.85e-05	0.00515	CcSEcCtD
Dinoprostone—Myocardial infarction—Prednisone—ankylosing spondylitis	9.79e-05	0.00512	CcSEcCtD
Dinoprostone—PTGIR—GPCR ligand binding—PTGER4—ankylosing spondylitis	9.77e-05	0.00226	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR ligand binding—PTGER4—ankylosing spondylitis	9.77e-05	0.00226	CbGpPWpGaD
Dinoprostone—Syncope—Prednisolone—ankylosing spondylitis	9.63e-05	0.00503	CcSEcCtD
Dinoprostone—Back pain—Triamcinolone—ankylosing spondylitis	9.56e-05	0.00499	CcSEcCtD
Dinoprostone—Loss of consciousness—Prednisolone—ankylosing spondylitis	9.44e-05	0.00493	CcSEcCtD
Dinoprostone—Asthma—Methotrexate—ankylosing spondylitis	9.36e-05	0.00489	CcSEcCtD
Dinoprostone—Angiopathy—Dexamethasone—ankylosing spondylitis	9.34e-05	0.00488	CcSEcCtD
Dinoprostone—Angiopathy—Betamethasone—ankylosing spondylitis	9.34e-05	0.00488	CcSEcCtD
Dinoprostone—Hypertension—Prednisolone—ankylosing spondylitis	9.27e-05	0.00485	CcSEcCtD
Dinoprostone—Arrhythmia—Dexamethasone—ankylosing spondylitis	9.2e-05	0.00481	CcSEcCtD
Dinoprostone—Arrhythmia—Betamethasone—ankylosing spondylitis	9.2e-05	0.00481	CcSEcCtD
Dinoprostone—ABCC5—Disease—ANTXR2—ankylosing spondylitis	8.99e-05	0.00208	CbGpPWpGaD
Dinoprostone—Syncope—Triamcinolone—ankylosing spondylitis	8.86e-05	0.00463	CcSEcCtD
Dinoprostone—Syncope—Methylprednisolone—ankylosing spondylitis	8.84e-05	0.00462	CcSEcCtD
Dinoprostone—Anaphylactic shock—Prednisolone—ankylosing spondylitis	8.77e-05	0.00458	CcSEcCtD
Dinoprostone—Loss of consciousness—Triamcinolone—ankylosing spondylitis	8.68e-05	0.00454	CcSEcCtD
Dinoprostone—Loss of consciousness—Methylprednisolone—ankylosing spondylitis	8.66e-05	0.00453	CcSEcCtD
Dinoprostone—Shock—Prednisolone—ankylosing spondylitis	8.63e-05	0.00451	CcSEcCtD
Dinoprostone—Cough—Triamcinolone—ankylosing spondylitis	8.62e-05	0.0045	CcSEcCtD
Dinoprostone—HPGDS—Metabolism—B3GNT2—ankylosing spondylitis	8.57e-05	0.00199	CbGpPWpGaD
Dinoprostone—Tachycardia—Prednisolone—ankylosing spondylitis	8.56e-05	0.00447	CcSEcCtD
Dinoprostone—Hypertension—Triamcinolone—ankylosing spondylitis	8.53e-05	0.00446	CcSEcCtD
Dinoprostone—Hypertension—Methylprednisolone—ankylosing spondylitis	8.51e-05	0.00445	CcSEcCtD
Dinoprostone—Hyperhidrosis—Prednisolone—ankylosing spondylitis	8.48e-05	0.00443	CcSEcCtD
Dinoprostone—Myalgia—Triamcinolone—ankylosing spondylitis	8.41e-05	0.00439	CcSEcCtD
Dinoprostone—Myalgia—Methylprednisolone—ankylosing spondylitis	8.39e-05	0.00438	CcSEcCtD
Dinoprostone—Arthralgia—Methylprednisolone—ankylosing spondylitis	8.39e-05	0.00438	CcSEcCtD
Dinoprostone—Flushing—Prednisone—ankylosing spondylitis	8.32e-05	0.00435	CcSEcCtD
Dinoprostone—PTGER2—GPCR downstream signaling—PTGER4—ankylosing spondylitis	8.17e-05	0.00189	CbGpPWpGaD
Dinoprostone—Angiopathy—Prednisone—ankylosing spondylitis	8.14e-05	0.00425	CcSEcCtD
Dinoprostone—Immune system disorder—Prednisone—ankylosing spondylitis	8.1e-05	0.00423	CcSEcCtD
Dinoprostone—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	8.06e-05	0.00421	CcSEcCtD
Dinoprostone—HPGDS—Integrated Pancreatic Cancer Pathway—TNF—ankylosing spondylitis	8.06e-05	0.00187	CbGpPWpGaD
Dinoprostone—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	8.04e-05	0.0042	CcSEcCtD
Dinoprostone—Syncope—Dexamethasone—ankylosing spondylitis	8.04e-05	0.0042	CcSEcCtD
Dinoprostone—Syncope—Betamethasone—ankylosing spondylitis	8.04e-05	0.0042	CcSEcCtD
Dinoprostone—Arrhythmia—Prednisone—ankylosing spondylitis	8.01e-05	0.00419	CcSEcCtD
Dinoprostone—Shock—Triamcinolone—ankylosing spondylitis	7.93e-05	0.00414	CcSEcCtD
Dinoprostone—Shock—Methylprednisolone—ankylosing spondylitis	7.91e-05	0.00414	CcSEcCtD
Dinoprostone—Loss of consciousness—Betamethasone—ankylosing spondylitis	7.88e-05	0.00412	CcSEcCtD
Dinoprostone—Loss of consciousness—Dexamethasone—ankylosing spondylitis	7.88e-05	0.00412	CcSEcCtD
Dinoprostone—Paraesthesia—Prednisolone—ankylosing spondylitis	7.87e-05	0.00411	CcSEcCtD
Dinoprostone—Tachycardia—Triamcinolone—ankylosing spondylitis	7.87e-05	0.00411	CcSEcCtD
Dinoprostone—Tachycardia—Methylprednisolone—ankylosing spondylitis	7.85e-05	0.0041	CcSEcCtD
Dinoprostone—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	7.79e-05	0.00407	CcSEcCtD
Dinoprostone—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	7.78e-05	0.00406	CcSEcCtD
Dinoprostone—Hypertension—Betamethasone—ankylosing spondylitis	7.74e-05	0.00404	CcSEcCtD
Dinoprostone—Hypertension—Dexamethasone—ankylosing spondylitis	7.74e-05	0.00404	CcSEcCtD
Dinoprostone—Myalgia—Dexamethasone—ankylosing spondylitis	7.63e-05	0.00399	CcSEcCtD
Dinoprostone—Myalgia—Betamethasone—ankylosing spondylitis	7.63e-05	0.00399	CcSEcCtD
Dinoprostone—PTGER3—GPCR downstream signaling—PTGER4—ankylosing spondylitis	7.54e-05	0.00175	CbGpPWpGaD
Dinoprostone—Hypotension—Methylprednisolone—ankylosing spondylitis	7.52e-05	0.00393	CcSEcCtD
Dinoprostone—Pain—Prednisolone—ankylosing spondylitis	7.5e-05	0.00392	CcSEcCtD
Dinoprostone—Pharyngitis—Methotrexate—ankylosing spondylitis	7.44e-05	0.00389	CcSEcCtD
Dinoprostone—PTGER2—Signaling by GPCR—PTGER4—ankylosing spondylitis	7.42e-05	0.00172	CbGpPWpGaD
Dinoprostone—Vision blurred—Prednisone—ankylosing spondylitis	7.36e-05	0.00384	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	7.35e-05	0.00384	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	7.33e-05	0.00383	CcSEcCtD
Dinoprostone—Anaphylactic shock—Betamethasone—ankylosing spondylitis	7.32e-05	0.00382	CcSEcCtD
Dinoprostone—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	7.32e-05	0.00382	CcSEcCtD
Dinoprostone—Paraesthesia—Triamcinolone—ankylosing spondylitis	7.24e-05	0.00378	CcSEcCtD
Dinoprostone—Paraesthesia—Methylprednisolone—ankylosing spondylitis	7.22e-05	0.00377	CcSEcCtD
Dinoprostone—Shock—Betamethasone—ankylosing spondylitis	7.2e-05	0.00376	CcSEcCtD
Dinoprostone—Shock—Dexamethasone—ankylosing spondylitis	7.2e-05	0.00376	CcSEcCtD
Dinoprostone—Dyspnoea—Triamcinolone—ankylosing spondylitis	7.19e-05	0.00376	CcSEcCtD
Dinoprostone—Tachycardia—Dexamethasone—ankylosing spondylitis	7.14e-05	0.00373	CcSEcCtD
Dinoprostone—Tachycardia—Betamethasone—ankylosing spondylitis	7.14e-05	0.00373	CcSEcCtD
Dinoprostone—Hyperhidrosis—Betamethasone—ankylosing spondylitis	7.07e-05	0.0037	CcSEcCtD
Dinoprostone—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	7.07e-05	0.0037	CcSEcCtD
Dinoprostone—Syncope—Prednisone—ankylosing spondylitis	7e-05	0.00366	CcSEcCtD
Dinoprostone—Pain—Triamcinolone—ankylosing spondylitis	6.89e-05	0.0036	CcSEcCtD
Dinoprostone—Loss of consciousness—Prednisone—ankylosing spondylitis	6.86e-05	0.00358	CcSEcCtD
Dinoprostone—PTGER3—Signaling by GPCR—PTGER4—ankylosing spondylitis	6.85e-05	0.00159	CbGpPWpGaD
Dinoprostone—Hypotension—Betamethasone—ankylosing spondylitis	6.84e-05	0.00357	CcSEcCtD
Dinoprostone—Hypotension—Dexamethasone—ankylosing spondylitis	6.84e-05	0.00357	CcSEcCtD
Dinoprostone—Angiopathy—Methotrexate—ankylosing spondylitis	6.8e-05	0.00355	CcSEcCtD
Dinoprostone—Immune system disorder—Methotrexate—ankylosing spondylitis	6.77e-05	0.00354	CcSEcCtD
Dinoprostone—Hypertension—Prednisone—ankylosing spondylitis	6.74e-05	0.00352	CcSEcCtD
Dinoprostone—Chills—Methotrexate—ankylosing spondylitis	6.72e-05	0.00351	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	6.67e-05	0.00348	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	6.67e-05	0.00348	CcSEcCtD
Dinoprostone—Myalgia—Prednisone—ankylosing spondylitis	6.65e-05	0.00347	CcSEcCtD
Dinoprostone—Arthralgia—Prednisone—ankylosing spondylitis	6.65e-05	0.00347	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	6.58e-05	0.00344	CcSEcCtD
Dinoprostone—Paraesthesia—Betamethasone—ankylosing spondylitis	6.57e-05	0.00343	CcSEcCtD
Dinoprostone—Paraesthesia—Dexamethasone—ankylosing spondylitis	6.57e-05	0.00343	CcSEcCtD
Dinoprostone—Hypersensitivity—Prednisolone—ankylosing spondylitis	6.46e-05	0.00338	CcSEcCtD
Dinoprostone—PTGER4—Signaling by GPCR—MMP3—ankylosing spondylitis	6.43e-05	0.00149	CbGpPWpGaD
Dinoprostone—Body temperature increased—Triamcinolone—ankylosing spondylitis	6.37e-05	0.00333	CcSEcCtD
Dinoprostone—Anaphylactic shock—Prednisone—ankylosing spondylitis	6.37e-05	0.00333	CcSEcCtD
Dinoprostone—Abdominal pain—Methylprednisolone—ankylosing spondylitis	6.36e-05	0.00332	CcSEcCtD
Dinoprostone—Back pain—Methotrexate—ankylosing spondylitis	6.31e-05	0.0033	CcSEcCtD
Dinoprostone—Shock—Prednisone—ankylosing spondylitis	6.27e-05	0.00327	CcSEcCtD
Dinoprostone—Pain—Dexamethasone—ankylosing spondylitis	6.26e-05	0.00327	CcSEcCtD
Dinoprostone—Pain—Betamethasone—ankylosing spondylitis	6.26e-05	0.00327	CcSEcCtD
Dinoprostone—Tachycardia—Prednisone—ankylosing spondylitis	6.22e-05	0.00325	CcSEcCtD
Dinoprostone—Hyperhidrosis—Prednisone—ankylosing spondylitis	6.16e-05	0.00322	CcSEcCtD
Dinoprostone—Vision blurred—Methotrexate—ankylosing spondylitis	6.15e-05	0.00321	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	5.98e-05	0.00313	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	5.98e-05	0.00313	CcSEcCtD
Dinoprostone—Hypersensitivity—Triamcinolone—ankylosing spondylitis	5.94e-05	0.0031	CcSEcCtD
Dinoprostone—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	5.93e-05	0.0031	CcSEcCtD
Dinoprostone—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	5.8e-05	0.00303	CcSEcCtD
Dinoprostone—Dizziness—Prednisolone—ankylosing spondylitis	5.8e-05	0.00303	CcSEcCtD
Dinoprostone—Asthenia—Triamcinolone—ankylosing spondylitis	5.78e-05	0.00302	CcSEcCtD
Dinoprostone—Body temperature increased—Betamethasone—ankylosing spondylitis	5.78e-05	0.00302	CcSEcCtD
Dinoprostone—Abdominal pain—Betamethasone—ankylosing spondylitis	5.78e-05	0.00302	CcSEcCtD
Dinoprostone—Abdominal pain—Dexamethasone—ankylosing spondylitis	5.78e-05	0.00302	CcSEcCtD
Dinoprostone—Body temperature increased—Dexamethasone—ankylosing spondylitis	5.78e-05	0.00302	CcSEcCtD
Dinoprostone—Asthenia—Methylprednisolone—ankylosing spondylitis	5.77e-05	0.00302	CcSEcCtD
Dinoprostone—Paraesthesia—Prednisone—ankylosing spondylitis	5.72e-05	0.00299	CcSEcCtD
Dinoprostone—Cough—Methotrexate—ankylosing spondylitis	5.69e-05	0.00297	CcSEcCtD
Dinoprostone—PTGFR—GPCR downstream signaling—PTGER4—ankylosing spondylitis	5.64e-05	0.00131	CbGpPWpGaD
Dinoprostone—Myalgia—Methotrexate—ankylosing spondylitis	5.55e-05	0.0029	CcSEcCtD
Dinoprostone—Chest pain—Methotrexate—ankylosing spondylitis	5.55e-05	0.0029	CcSEcCtD
Dinoprostone—Arthralgia—Methotrexate—ankylosing spondylitis	5.55e-05	0.0029	CcSEcCtD
Dinoprostone—Rash—Prednisolone—ankylosing spondylitis	5.53e-05	0.00289	CcSEcCtD
Dinoprostone—Dermatitis—Prednisolone—ankylosing spondylitis	5.52e-05	0.00289	CcSEcCtD
Dinoprostone—PTGIR—GPCR downstream signaling—PTGER4—ankylosing spondylitis	5.52e-05	0.00128	CbGpPWpGaD
Dinoprostone—PTGER1—GPCR downstream signaling—PTGER4—ankylosing spondylitis	5.52e-05	0.00128	CbGpPWpGaD
Dinoprostone—Diarrhoea—Methylprednisolone—ankylosing spondylitis	5.5e-05	0.00288	CcSEcCtD
Dinoprostone—Headache—Prednisolone—ankylosing spondylitis	5.49e-05	0.00287	CcSEcCtD
Dinoprostone—Dizziness—Triamcinolone—ankylosing spondylitis	5.33e-05	0.00279	CcSEcCtD
Dinoprostone—Anaphylactic shock—Methotrexate—ankylosing spondylitis	5.32e-05	0.00278	CcSEcCtD
Dinoprostone—Dizziness—Methylprednisolone—ankylosing spondylitis	5.32e-05	0.00278	CcSEcCtD
Dinoprostone—ABCC5—Disease—B3GNT2—ankylosing spondylitis	5.3e-05	0.00123	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling by GPCR—MMP3—ankylosing spondylitis	5.28e-05	0.00122	CbGpPWpGaD
Dinoprostone—Asthenia—Dexamethasone—ankylosing spondylitis	5.25e-05	0.00274	CcSEcCtD
Dinoprostone—Asthenia—Betamethasone—ankylosing spondylitis	5.25e-05	0.00274	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Prednisone—ankylosing spondylitis	5.21e-05	0.00272	CcSEcCtD
Dinoprostone—Nausea—Prednisolone—ankylosing spondylitis	5.21e-05	0.00272	CcSEcCtD
Dinoprostone—Hyperhidrosis—Methotrexate—ankylosing spondylitis	5.15e-05	0.00269	CcSEcCtD
Dinoprostone—Vomiting—Triamcinolone—ankylosing spondylitis	5.13e-05	0.00268	CcSEcCtD
Dinoprostone—PTGFR—Signaling by GPCR—PTGER4—ankylosing spondylitis	5.12e-05	0.00119	CbGpPWpGaD
Dinoprostone—Vomiting—Methylprednisolone—ankylosing spondylitis	5.12e-05	0.00267	CcSEcCtD
Dinoprostone—Rash—Triamcinolone—ankylosing spondylitis	5.08e-05	0.00266	CcSEcCtD
Dinoprostone—Dermatitis—Triamcinolone—ankylosing spondylitis	5.08e-05	0.00265	CcSEcCtD
Dinoprostone—Rash—Methylprednisolone—ankylosing spondylitis	5.07e-05	0.00265	CcSEcCtD
Dinoprostone—Dermatitis—Methylprednisolone—ankylosing spondylitis	5.07e-05	0.00265	CcSEcCtD
Dinoprostone—Headache—Triamcinolone—ankylosing spondylitis	5.05e-05	0.00264	CcSEcCtD
Dinoprostone—Headache—Methylprednisolone—ankylosing spondylitis	5.04e-05	0.00263	CcSEcCtD
Dinoprostone—Body temperature increased—Prednisone—ankylosing spondylitis	5.04e-05	0.00263	CcSEcCtD
Dinoprostone—Abdominal pain—Prednisone—ankylosing spondylitis	5.04e-05	0.00263	CcSEcCtD
Dinoprostone—PTGIR—Signaling by GPCR—PTGER4—ankylosing spondylitis	5.01e-05	0.00116	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—PTGER4—ankylosing spondylitis	5.01e-05	0.00116	CbGpPWpGaD
Dinoprostone—Diarrhoea—Betamethasone—ankylosing spondylitis	5.01e-05	0.00262	CcSEcCtD
Dinoprostone—Diarrhoea—Dexamethasone—ankylosing spondylitis	5.01e-05	0.00262	CcSEcCtD
Dinoprostone—Hypotension—Methotrexate—ankylosing spondylitis	4.98e-05	0.0026	CcSEcCtD
Dinoprostone—PTGER3—Signaling by GPCR—MMP3—ankylosing spondylitis	4.88e-05	0.00113	CbGpPWpGaD
Dinoprostone—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	4.85e-05	0.00253	CcSEcCtD
Dinoprostone—Dizziness—Dexamethasone—ankylosing spondylitis	4.84e-05	0.00253	CcSEcCtD
Dinoprostone—Dizziness—Betamethasone—ankylosing spondylitis	4.84e-05	0.00253	CcSEcCtD
Dinoprostone—Nausea—Triamcinolone—ankylosing spondylitis	4.79e-05	0.0025	CcSEcCtD
Dinoprostone—Paraesthesia—Methotrexate—ankylosing spondylitis	4.78e-05	0.0025	CcSEcCtD
Dinoprostone—Nausea—Methylprednisolone—ankylosing spondylitis	4.78e-05	0.0025	CcSEcCtD
Dinoprostone—Dyspnoea—Methotrexate—ankylosing spondylitis	4.75e-05	0.00248	CcSEcCtD
Dinoprostone—Hypersensitivity—Prednisone—ankylosing spondylitis	4.69e-05	0.00245	CcSEcCtD
Dinoprostone—Vomiting—Betamethasone—ankylosing spondylitis	4.65e-05	0.00243	CcSEcCtD
Dinoprostone—Vomiting—Dexamethasone—ankylosing spondylitis	4.65e-05	0.00243	CcSEcCtD
Dinoprostone—Rash—Dexamethasone—ankylosing spondylitis	4.61e-05	0.00241	CcSEcCtD
Dinoprostone—Rash—Betamethasone—ankylosing spondylitis	4.61e-05	0.00241	CcSEcCtD
Dinoprostone—Dermatitis—Dexamethasone—ankylosing spondylitis	4.61e-05	0.00241	CcSEcCtD
Dinoprostone—Dermatitis—Betamethasone—ankylosing spondylitis	4.61e-05	0.00241	CcSEcCtD
Dinoprostone—Headache—Betamethasone—ankylosing spondylitis	4.58e-05	0.00239	CcSEcCtD
Dinoprostone—Headache—Dexamethasone—ankylosing spondylitis	4.58e-05	0.00239	CcSEcCtD
Dinoprostone—Asthenia—Prednisone—ankylosing spondylitis	4.57e-05	0.00239	CcSEcCtD
Dinoprostone—Pain—Methotrexate—ankylosing spondylitis	4.55e-05	0.00238	CcSEcCtD
Dinoprostone—ABCC5—Metabolism—B3GNT2—ankylosing spondylitis	4.44e-05	0.00103	CbGpPWpGaD
Dinoprostone—PTGER2—Signaling Pathways—PTGER4—ankylosing spondylitis	4.38e-05	0.00101	CbGpPWpGaD
Dinoprostone—Diarrhoea—Prednisone—ankylosing spondylitis	4.36e-05	0.00228	CcSEcCtD
Dinoprostone—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	4.35e-05	0.00227	CcSEcCtD
Dinoprostone—Nausea—Betamethasone—ankylosing spondylitis	4.35e-05	0.00227	CcSEcCtD
Dinoprostone—Nausea—Dexamethasone—ankylosing spondylitis	4.35e-05	0.00227	CcSEcCtD
Dinoprostone—Dizziness—Prednisone—ankylosing spondylitis	4.21e-05	0.0022	CcSEcCtD
Dinoprostone—Body temperature increased—Methotrexate—ankylosing spondylitis	4.21e-05	0.0022	CcSEcCtD
Dinoprostone—Abdominal pain—Methotrexate—ankylosing spondylitis	4.21e-05	0.0022	CcSEcCtD
Dinoprostone—Vomiting—Prednisone—ankylosing spondylitis	4.05e-05	0.00212	CcSEcCtD
Dinoprostone—PTGER3—Signaling Pathways—PTGER4—ankylosing spondylitis	4.04e-05	0.000937	CbGpPWpGaD
Dinoprostone—Rash—Prednisone—ankylosing spondylitis	4.02e-05	0.0021	CcSEcCtD
Dinoprostone—Dermatitis—Prednisone—ankylosing spondylitis	4.01e-05	0.0021	CcSEcCtD
Dinoprostone—Headache—Prednisone—ankylosing spondylitis	3.99e-05	0.00209	CcSEcCtD
Dinoprostone—Hypersensitivity—Methotrexate—ankylosing spondylitis	3.92e-05	0.00205	CcSEcCtD
Dinoprostone—CYP11A1—Metabolism—B3GNT2—ankylosing spondylitis	3.89e-05	0.0009	CbGpPWpGaD
Dinoprostone—Asthenia—Methotrexate—ankylosing spondylitis	3.82e-05	0.002	CcSEcCtD
Dinoprostone—PTGER4—Signaling Pathways—MMP3—ankylosing spondylitis	3.8e-05	0.00088	CbGpPWpGaD
Dinoprostone—Nausea—Prednisone—ankylosing spondylitis	3.78e-05	0.00198	CcSEcCtD
Dinoprostone—PTGFR—Signaling by GPCR—MMP3—ankylosing spondylitis	3.65e-05	0.000844	CbGpPWpGaD
Dinoprostone—Diarrhoea—Methotrexate—ankylosing spondylitis	3.64e-05	0.0019	CcSEcCtD
Dinoprostone—PTGIR—Signaling by GPCR—MMP3—ankylosing spondylitis	3.57e-05	0.000826	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling by GPCR—MMP3—ankylosing spondylitis	3.57e-05	0.000826	CbGpPWpGaD
Dinoprostone—Dizziness—Methotrexate—ankylosing spondylitis	3.52e-05	0.00184	CcSEcCtD
Dinoprostone—Vomiting—Methotrexate—ankylosing spondylitis	3.39e-05	0.00177	CcSEcCtD
Dinoprostone—Rash—Methotrexate—ankylosing spondylitis	3.36e-05	0.00175	CcSEcCtD
Dinoprostone—Dermatitis—Methotrexate—ankylosing spondylitis	3.35e-05	0.00175	CcSEcCtD
Dinoprostone—Headache—Methotrexate—ankylosing spondylitis	3.34e-05	0.00174	CcSEcCtD
Dinoprostone—Nausea—Methotrexate—ankylosing spondylitis	3.16e-05	0.00165	CcSEcCtD
Dinoprostone—PTGER2—Signaling Pathways—MMP3—ankylosing spondylitis	3.12e-05	0.000723	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—PTGER4—ankylosing spondylitis	3.02e-05	0.0007	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—PTGER4—ankylosing spondylitis	2.96e-05	0.000685	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—PTGER4—ankylosing spondylitis	2.96e-05	0.000685	CbGpPWpGaD
Dinoprostone—PTGER3—Signaling Pathways—MMP3—ankylosing spondylitis	2.88e-05	0.000667	CbGpPWpGaD
Dinoprostone—CYP1A2—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	2.86e-05	0.000662	CbGpPWpGaD
Dinoprostone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	2.86e-05	0.000662	CbGpPWpGaD
Dinoprostone—SLCO1A2—Metabolism—B3GNT2—ankylosing spondylitis	2.85e-05	0.00066	CbGpPWpGaD
Dinoprostone—CYP19A1—Metabolism—B3GNT2—ankylosing spondylitis	2.58e-05	0.000596	CbGpPWpGaD
Dinoprostone—SLCO1B1—Metabolism—B3GNT2—ankylosing spondylitis	2.44e-05	0.000564	CbGpPWpGaD
Dinoprostone—SLC22A2—Metabolism—B3GNT2—ankylosing spondylitis	2.23e-05	0.000517	CbGpPWpGaD
Dinoprostone—PTGFR—Signaling Pathways—MMP3—ankylosing spondylitis	2.15e-05	0.000499	CbGpPWpGaD
Dinoprostone—ABCC5—Disease—HLA-A—ankylosing spondylitis	2.14e-05	0.000497	CbGpPWpGaD
Dinoprostone—PTGER1—Signaling Pathways—MMP3—ankylosing spondylitis	2.11e-05	0.000488	CbGpPWpGaD
Dinoprostone—PTGIR—Signaling Pathways—MMP3—ankylosing spondylitis	2.11e-05	0.000488	CbGpPWpGaD
Dinoprostone—SLC22A1—Metabolism—B3GNT2—ankylosing spondylitis	2.08e-05	0.000482	CbGpPWpGaD
Dinoprostone—CYP1A2—Metabolism—B3GNT2—ankylosing spondylitis	9.74e-06	0.000225	CbGpPWpGaD
